Key clinical point:
Major finding: Zanubrutinib had an overall response rate of 92%, and the estimated 12-month progression-free survival rate was 89%.
Study details: A phase 1 study with 73 patients evaluable for efficacy in this analysis.
Disclosures: The trial is sponsored by BeiGene. Dr. Tam reported financial relationships with BeiGene and other companies.
Leukemia & Lymphoma 2018
Must Reads in Indolent Lymphoma
Follicular lymphoma: MRD response correlates with outcomes , Pott C et al. ASH 2018, Abstract 396.